EGFR and leukoencephalopathy with calcifications and cysts: Indeed, when efficacy of anti-EGFR agents was compared to that of Bevacizumab after stratification by site of primary tumor, we found that the former were associated with a significant advantage in median OS (40.7 vs 28.6 months) and PFS (12.4 vs 10.7) in the group of patients with LCC, while no difference was observed in those with RCC.